

*How NBs will cope with appropriate surveillance according to MDD and new conformity assessment for MDR at same time?*

TÜV Süd Product Service GmbH  
Hans-Heiner Junker  
Senior International Affairs Manager  
München




---

**Mehr Wert.  
Mehr Vertrauen.**


**Add value.  
Inspire trust.**

# One – out of many - Challenge

## Challenge




## Relationship Personnel – Scope of Designation



# Transition from MDD to MDR

## Challenges to combine

- Different QMS Systems (manufacturer)
- Several jurisdictions
  - MDD, MDR, ISO, MDSAP, ...
- Big time on TD assessment
  - New MDR Sampling plans
  - More time for assessment of one TD
- MDD TD Assessment
  - PSUR Requirements
  - PMS, PMCF
  - Significant Changes
- One File for MDD in 2022 - the very next year for MDR?
- Some Notified Bodies increased their staff dramatically (2- or 3 fold) in the past years



# What we are working on

- Providing input on: Harmonization on global level
- Providing input on: Harmonization on European level
- Input means:
  - What means: significant changes according to MDR Article 120?
  - What means: appropriate surveillance of MDD/AIMD/IVDR?
  - Harmonization of auditors and experts by providing training
  - Understanding the effect of the new nomenclature on sampling plans
  - Many questions regarding classification. What is a screw?
  - Content of Technical Documentation: data from production phase, language, details
  - .....
- Input means also: additional resources for NBCG/NB-Med



Very  
First  
Experience

# Planning & Preparation

- Huge focus on the contract review and application
- Authorization requirements (especially for legacy devices) broader; more scope necessary >> Audit team
- Demonstrating competency for notified body personnel more complex
- Full auditing readiness of manufactures not given
  - Delay of audit schedule
- Stage 1 / 2 setup is no challenge so far

# Auditing

- SOPs for requirements from the MDR sometimes not in place due to focus on ISO 13485
  - Technical Documentation requirements
    - create
    - update
    - control
  - Language requirements
    - Manuals / Labels / Information provided with the device
    - Information provided through Software User Interfaces
    - Information provided on devices
  - CE Marking of devices (Hardware / Software)
  - Selection of applicable Risk Class and Conformity Assessment Procedure



# Technical Documentation Assessment

```

j.GPL Licenses,
e: e["undefined"]?typeof jQuery?jQuery(window,Zepto)
preventDefault()({preventDefault:()=>{target:ajaxSubmit}})function
{var n=a.closest("typesubmit");if(0==n.length)return n(0)
...
}

```

- Consistency was expected to be a huge issue, and it truly is.
  - Wording and consistency throughout the TD of
    - i. Intended purpose
    - ii. Indications
    - iii. Contraindications
    - iv. Risks, remaining risks, risk benefit ratio
    - v. Claims
  
- Completeness of TD
  - Promotional materials >> CER
  - Language requirements and translations
  - Process data ?
  - Verification / Validation methods (GSPR and general)
  - Standards applied and documented evidence showing compliance
  - Information on design stages applied
  - Information on pre-clinical testing
  - Post market activities unclear

# Conclusions

- So far no major issues discovered
  - expected challenges did occur
- Documentation effort has increased
  - within expected range
- Consistency & completeness remains the biggest issue
  - More requirements increase this issue directly



# Thanks



How NBs will cope with appropriate surveillance according to MDD and new conformity assessment for MDR at same time?

Hans-Heiner Junker  
TÜV Süd Product Service

Telefon: +49 89-5008-4113  
E-Mail: [Hans-Heiner.Junker@tuev-sued.de](mailto:Hans-Heiner.Junker@tuev-sued.de)

More information on: [www.tuev-sued.de/mhs](http://www.tuev-sued.de/mhs)